Compare Amylx Pharmaceuticals Inc (AMLX) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Live Nation Entertainment, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Live Nation Entertainment, Inc. trades at $179.69 (market cap $41.84B). The key difference: Live Nation Entertainment, Inc. is far larger — about 21.1× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMLX | LYV | |
|---|---|---|
Market Cap | $1.98B | $41.84B |
Sector | Health | Industrials |
52-Week High | $18.70 | $186.59 |
52-Week Low | $7.64 | $125.61 |
Enterprise Value | $1.70B | $43.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Live Nation (LYV) trades at $179.79, down 1.53% today, with strong analyst support (88.6% buy ratings) and a $200.20 consensus price target. The stock shows bullish technical signals despite recent earnings misses, with revenue growth to $25.2B in 2025 but net margins narrowing to 1.96%. Recent news highlights strong concert demand and strategic initiatives, though legal challenges and cost pressures remain concerns.
Outlook remains positive based on analyst consensus and projected cash flow growth, but investors face risks from volatile earnings, high debt levels, and regulatory scrutiny. The stock's elevated P/E of 117.5 reflects growth expectations that must materialize to justify current valuations amid competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
